The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RNAC | -61.62% | -87.95% | -34.48% | -79% |
| S&P | +17.45% | +75.43% | +11.88% | +50% |
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides RNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Gaithersburg, MD.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $947.00K | 0.0% |
| Gross Profit | $947.00K | 0.0% |
| Gross Margin | 100.00% | 0.0% |
| Market Cap | $187.49M | 0.0% |
| Net Income | -$92,576.00K | 0.0% |
| EBITDA | -$21,222.00K | -246.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $125.14M | 0.0% |
| Accounts Receivable | $1.12M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.53M | 0.0% |
| Short Term Debt | $4.15M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -102.11% | 0.0% |
| Return On Invested Capital | -407.41% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20,116.00K | -25.5% |
| Operating Free Cash Flow | -$17,521.00K | -21.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 418.81 | -12.37 | -105.15 | -5.23 | 84.78% |
| Price to Sales | 4.08 | 8.88 | 7.22 | 67.05 | - |
| Price to Tangible Book Value | -1.59 | -1.22 | -1.32 | -0.80 | -16.46% |
| Enterprise Value to EBITDA | 12.10 | -7.38 | -6.51 | -3.54 | -67.85% |
| Return on Equity | -938.4% | - | |||
| Total Debt | $14.07M | $13.35M | $12.60M | $12.68M | -13.48% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
